OxVax
Description: OxVax develops next-gen dendritic cell vaccines for solid tumors using iPSC-derived CD141+XCR1+ DCs, offering autologous or semi-allogeneic treatments.
Country: UK
Based in: Oxford
Founded: 2021
Funding Stage: Pre-Seed
Tags: ['Biotechnology', 'Therapeutics']
ACCESS DIRECTORY
Details about how we process your information are available in our Privacy Policy.
